Adia Nutrition Inc. Secures IRB Approval for Autism Clinical Study
Adia Nutrition Inc. has received approval from the independent Institutional Review Board (IRB) BeyondBound for its clinical study protocol focused on Autism Spectrum Disorder (ASD). The approved study, led by Adia Med of Winter Park LLC, will enroll 100 children ages 3-12 to investigate the therapeutic benefits of combining glutathione with umbilical cord blood-derived stem cells compared to glutathione alone. The study has been submitted to ClinicalTrials.gov and is in final review before becoming publicly visible. No grant or funding from multiple organizations is mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 278050) on December 15, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。